Goldman Sachs Group Inc. Reiterates “GBX 1,800” Price Target for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK) received a GBX 1,800 ($21.94) target price from analysts at Goldman Sachs Group Inc. in a research note issued on Wednesday. The firm presently has a a “buy” rating on the stock. Goldman Sachs Group Inc.’s price target suggests a potential upside of 7.98% from the stock’s current price.
A number of other analysts have also recently issued reports on GSK. Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 21st. Citigroup Inc. reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Thursday, June 23rd. Credit Suisse Group AG reissued a “neutral” rating and issued a GBX 1,440 ($17.55) price objective on shares of GlaxoSmithKline plc in a research note on Monday, June 27th. Deutsche Bank AG reissued a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday, June 27th. Finally, BNP Paribas reissued a “neutral” rating and issued a GBX 1,430 ($17.43) price objective on shares of GlaxoSmithKline plc in a research note on Monday, June 27th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of GBX 1,677.42 ($20.44).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1660.665 on Wednesday. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56. The stock’s 50 day moving average is GBX 1,651.49 and its 200-day moving average is GBX 1,567.94. The company’s market capitalization is GBX 80.72 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/goldman-sachs-group-inc-reiterates-gbx-1800-price-target-for-glaxosmithkline-plc-gsk.html
The business also recently declared a dividend, which was paid on Thursday, October 13th. Investors of record on Thursday, August 11th were paid a GBX 19 ($0.23) dividend. This represents a yield of 1.12%. The ex-dividend date of this dividend was Thursday, August 11th.
In related news, insider Slaoui,Moncef purchased 28 shares of GlaxoSmithKline plc stock in a transaction that occurred on Friday, August 12th. The shares were bought at an average price of GBX 2,208 ($26.91) per share, with a total value of £618.24 ($753.49). Also, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.63), for a total transaction of £169,300 ($206,337.60).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.